Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors
- 17 April 2023
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (5) , 606-613
Abstract
The mitogen-activated protein kinase signaling cascade is conserved across eukaryotes, where it plays a critical role in the regulation of activities including proliferation, differentiation, and stress responses. This pathway propagates external stimuli through a series of phosphorylation events, which allows external signals to influence metabolic and transcriptional activities. Within the cascade, MEK, or MAP2K, enzymes occupy a molecular crossroads immediately upstream to significant signal divergence and cross-talk. One such kinase, MAP2K7, also known as MEK7 and MKK7, is a protein of great interest in the molecular pathophysiology underlying pediatric T cell acute lymphoblastic leukemia (T-ALL). Herein, we describe the rational design, synthesis, evaluation, and optimization of a novel class of irreversible MAP2K7 inhibitors. With a streamlined one-pot synthesis, favorable in vitro potency and selectivity, and promising cellular activity, this novel class of compounds wields promise as a powerful tool in the study of pediatric T-ALL.Keywords
All Related Versions
Funding Information
- National Cancer Institute (R01CA188015, R01CA207086)
- Division of Graduate Education (DGE-1324585)
- National Institutes of Health (F30DA050445, F31CA228431, F31CA250353, T32 GM008231, T32GM008152, T32GM105538)
- Northwestern University
This publication has 57 references indexed in Scilit:
- Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An UpdateJournal of Clinical Oncology, 2011
- Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemiaBlood, 2010
- Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium StudyJournal of Clinical Oncology, 2010
- Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsBlood, 2008
- Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase StatesJournal of Medicinal Chemistry, 2008
- Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975‐1999Cancer, 2008
- Syntheses of a Triad of Flt3 Kinase Inhibitors: From Bench to Pilot PlantOrganic Process Research & Development, 2008
- Trends in childhood cancer incidence in the U.S. (1992–2004)Cancer, 2007
- Chronic Health Conditions in Adult Survivors of Childhood CancerNew England Journal of Medicine, 2006
- Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancerJournal of Cellular Physiology, 2001